The CB1 receptor agonist WIN 55,212-2 fails to evoke physical dependence in Swiss mice

Barbara Budzyńska; Grażyna Biała

Authors

Barbara Budzyńska Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Poland Author https://orcid.org/0000-0001-5917-9285
Grażyna Biała Department of Pharmacology and Pharmacodynamics, Medical University of Lublin, Poland Author https://orcid.org/0000-0001-8270-9635

Keywords:

cannabinoids, WIN 55,212-2, rimonabant, dependence, withdrawal, mice

Abstract

Potential ability of cannabinoids to produce dependence is still a controversial issue. In our study, in order to examine the cannabinoid physical dependence phenomenon we administered CB1 receptor agonist WIN55,212-2, afterwards, in order to precipitate the withdrawal signs, chronically WIN 55,212-2 treated mice received an injection of rimonabant – an antagonist of CB1 receptors. The present study does not show that administration of rimonabant in mice chronically treated with the WIN 55,212-2 precipitated a signs of withdrawal syndrome.

References

1. Aceto M.D. et al.: Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55,212-2. Eur. J. Pharmacol., 416, 75, 20011.

2. Aggarwal S.K. et al.: Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J. Opioid Manag., 5(3), 153, 2009.

3. Becker G.L. et al.: Precipitated and conditioned withdrawal in morphine-treated rats. Psychopharmacology, 209, 85, 2010.

4. Biala G., Weglinska B.: Blockade of the expression of mecamylamine-precipitated nicotine withdrawal by calcium channel antagonists. Pharmacol. Res., 51, 483, 2005.

5. Budney A.J., Hughes J.R.: The cannabis withdrawal syndrome. Curr. Opin. Psychiatry., 19, 233, 2006.

6. Castañé A. et al.: Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice. Br. J. Pharmacol., 142, 1309, 2004.

7. De Vries T.J., Schoffelmeer A.N.: Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol. Sci., 26, 420, 2005.

8. González S. et al.: Cannabinoid tolerance and dependence. a review of studies in laboratory animals. Pharmacol. Biochem. Behav., 81, 300, 2005.

9. Griffin G. et al.: Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J. Pharmacol. Exp. Ther., 285, 553, 1998.

10. Howlett C. et al.: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161, 2002.

11. Jones R.T. et al.: Clinical studies of cannabis tolerance and dependence. Ann. N Y Acad. Sci., 282, 221, 1976.

12. Ledent C. et al.: Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 knockout mice. Science, 283, 401, 1999.

13. Maldonado R., Rodríguez de Fonseca F.: Cannabinoid addiction: behavioral models and neural correlates. J. Neurosci., 22, 3326, 2002.

14. Melis M. et al.: Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J. Neurosci., 24, 53, 2004.

15. Nocerino E. et al.: Cannabis and cannabinoid receptors. Fitoterapia, 71, 6, 2000.

16. Panagis G. et al.: Behavioral pharmacology of cannabinoids with a focus on preclinical models for studying reinforcing and dependence-producing properties. Curr. Drug Abuse Rev., 1, 350, 2008.

17. Szabo B. et al.: Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur. J. Neurosci., 15, 2057, 2002.